A survey by MJH Life Science reveals how patient communication has evolved across clinical practices in the wake of COVID-19.
According to a survey by MJH Life Sciences™, physicians across multiple specialties have had increased communication with patients since the onset of coronavirus disease 2019 (COVID-19), mostly focused on acute, chronic, and COVID-19–related issues. Increased communication between physicians and patients is in large part due to patient apprehension about receiving health services in person as well as the need for practitioners to inform their patients that services are still available.
Based on the survey, reasons for utilizing telehealth in the future include flexibility, safety of staff and patients, adaptability, communication, and compassion. The big-gest concern for many physicians regarding reopening facilities was the ability to create a safe environment for patients and staff.
Physicians surveyed included practicing oncologists, inter-nal medicine and family/general practice, neurology, pediat-rics, obstetrician/gynecology, dermatology, ophthalmology, psychiatry, and rheumatology. In total, 1324 responses were received, with 43 responses from oncology specialists and 243 responses from primary care physicians.
Almost 90% of primary care physicians who participated in the survey inform their patients about COVID-19 testing opportunities. Respons-es showed that more than half of these physicians (54%) will continue using telehealth and other remote services more often to communicate with their patients, even when the pandemic is over. A challenge for this space is providing care for patients who lack access to technology and may find it more difficult to take advantage of telehealth services, according to 23% of primary care physicians surveyed.
Oncology specialists reported that surgical procedures were a priority once in-person vis-its resume, followed closely by medical visits. They also noted that they will continue to use telemedicine for screening and communication even after practices reopen.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Participants Discuss Frontline Immunotherapy Followed by ADC for Metastatic Cervical Cancer
December 19th 2024During a Case-Based Roundtable® event, Ramez N. Eskander, MD, and participants discussed first and second-line therapy decisions for a patient with PD-L1–positive cervical cancer in the frontline metastatic setting.
Read More
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
December 18th 2024During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Read More